MX2019013801A - Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos. - Google Patents

Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.

Info

Publication number: MX2019013801A
Authority: MX; Mexico
Prior art keywords: compounds; mic; amino acid; relates; acid extension
Prior art date: 2017-05-23

Application number

MX2019013801A

Other languages

English (en)

Spanish (es)

Inventor

Waldemar Conde Frieboes Kilian

Beck Jørgensen Sebastian

zhang Xujia

Gao Xiang

Guan Hongtao

Thøgersen Henning

Sass-Ørum Kristian

Fogh Iversen Lars

Nørgaard Per

Tage Hansen Kristian

Wang Yi

Wieczorek Birgit

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-23

Filing date

2018-05-23

Publication date

2020-01-30

2018-05-23 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2020-01-30 Publication of MX2019013801A publication Critical patent/MX2019013801A/es

Links

150000001875 compounds Chemical class 0.000 title abstract 6
102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 title 1
101710180672 Regulator of MON1-CCZ1 complex Proteins 0.000 title 1
102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 4
101710194460 Growth/differentiation factor 15 Proteins 0.000 abstract 4
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
125000000539 amino acid group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biophysics (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

MX2019013801A 2017-05-23 2018-05-23 Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos. MX2019013801A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CN2017085576		2017-05-23
CN2017113335		2017-11-28
PCT/EP2018/063476 WO2018215525A1 (fr)	2017-05-23	2018-05-23	Composés mic-1 et utilisations associées

Publications (1)

Publication Number	Publication Date
MX2019013801A true MX2019013801A (es)	2020-01-30

Family

ID=62567604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2019013801A MX2019013801A (es)	2017-05-23	2018-05-23	Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.

Country Status (17)

Country	Link
US (3)	US20200079829A1 (fr)
EP (1)	EP3630805A1 (fr)
JP (1)	JP7015322B2 (fr)
KR (1)	KR20200010353A (fr)
CN (1)	CN111183148A (fr)
AU (1)	AU2018272911B2 (fr)
BR (1)	BR112019024102A2 (fr)
CA (1)	CA3064320A1 (fr)
CL (1)	CL2019003441A1 (fr)
CO (1)	CO2019013768A2 (fr)
MA (1)	MA48956A (fr)
MX (1)	MX2019013801A (fr)
PE (1)	PE20200514A1 (fr)
PH (1)	PH12019550241A1 (fr)
RU (1)	RU2019141031A (fr)
TW (1)	TWI710377B (fr)
WO (1)	WO2018215525A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
KR102433503B1 (ko)	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	Mic-1 화합물 및 이것의 사용
TWI710377B (zh) *	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
EA202191105A1 (ru)	2018-10-22	2021-08-03	Янссен Фармацевтика Нв	Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP4041281B1 (fr)	2019-10-04	2025-11-26	Amgen Inc.	Utilisation de gdf15 pour le traitement du syndrôme cardiométabolique et d'autres maladies
EP4085077A4 (fr) *	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	Protéines de fusion de glp-1 et de gdf15 et leurs conjugués
CN114729060B (zh)	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
CN115947820A (zh) *	2021-10-08	2023-04-11	北京志道生物科技有限公司	一种水溶性提高的il-2衍生物
WO2023154953A1 (fr)	2022-02-14	2023-08-17	Ngm Biopharmaceuticals, Inc.	Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes
EP4323413A4 (fr)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	Compositions pharmaceutiques liquides de conjugués polypeptidiques et leurs procédés d'utilisation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2213743A1 (fr)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
CN1241946C (zh)	2002-07-01	2006-02-15	美国福源集团	对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
EP2441466B1 (fr)	2004-04-13	2014-07-23	St Vincent's Hospital Sydney Limited	Agent inhibiteur de MIC-1
US20050256576A1 (en)	2004-05-13	2005-11-17	Moskowitz Nathan C	Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs
EP2194064A1 (fr)	2004-05-13	2010-06-09	Eli Lilly & Company	Protéines de fusion FGF-21
EP1771467A2 (fr)	2004-07-26	2007-04-11	Asterion Limited	Lieurs
JP2010505437A (ja)	2006-10-13	2010-02-25	ノボノルディスクヘルスケアアーゲー	塩基性タンパク質タグに融合したプロセシング酵素
JP2010536341A (ja)	2007-08-15	2010-12-02	アムニクス，インコーポレイテッド	生物学的に活性なポリペプチドの特性を改変するための組成物および方法
US20100317057A1 (en)	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
ES2561208T3 (es)	2008-09-12	2016-02-25	Novo Nordisk A/S	Método de acilación de un péptido o una proteína
CN102361647B (zh) *	2009-01-23	2018-02-16	诺沃-诺迪斯克有限公司	具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2610356T3 (es) *	2009-02-03	2017-04-27	Amunix Operating Inc.	Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP2694092B1 (fr)	2011-04-08	2017-01-04	Amgen Inc.	Méthode de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur 15 de différenciation de croissance (gdf-15)
EP3683228A3 (fr)	2012-01-26	2020-07-29	Amgen Inc.	Polypeptides du facteur de croissance et de différenciation 15 (gdf-15)
CA2862516C (fr) *	2012-03-27	2023-02-14	Ngm Biopharmaceuticals, Inc.	Compositions et methodes d'utilisation pour le traitement de troubles metaboliques
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
KR101993714B1 (ko)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9862752B2 (en)	2013-07-31	2018-01-09	Amgen Inc.	Growth differentiation factor 15 (GDF-15) constructs
HK1225740A1 (zh)	2013-08-22	2017-09-15	Acceleron Pharma Inc.	TGF-β受体II型变体及其用途
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) *	2014-06-24	2018-07-24	Ново Нордиск А/С	Mic-1 слитные белки и их применение
AR103246A1 (es)	2014-12-23	2017-04-26	Novo Nordiks As	Derivados de fgf21 y sus usos
MA41794A (fr) *	2015-03-18	2018-01-23	The California Institute For Biomedical Res	Agents thérapeutiques modifiés et compositions associées
GB201517528D0 (en)	2015-10-02	2015-11-18	Julius Maximillians Universitãt Würzburg	GDF-15 as a diagnosis marker for melanoma
CN108463246B (zh)	2015-10-02	2025-02-28	尤利乌斯·马克西米利安维尔茨堡大学	使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
FI3356827T3 (fi)	2015-10-02	2024-01-03	Univ Wuerzburg J Maximilians	GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
JP6946304B2 (ja)	2015-12-22	2021-10-06	ノバルティスアーゲー	増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
KR102433503B1 (ko) *	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	Mic-1 화합물 및 이것의 사용
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途

2018
- 2018-05-21 TW TW107117256A patent/TWI710377B/zh not_active IP Right Cessation
- 2018-05-23 MX MX2019013801A patent/MX2019013801A/es unknown
- 2018-05-23 KR KR1020197037299A patent/KR20200010353A/ko not_active Withdrawn
- 2018-05-23 JP JP2019563484A patent/JP7015322B2/ja not_active Expired - Fee Related
- 2018-05-23 CA CA3064320A patent/CA3064320A1/fr not_active Withdrawn
- 2018-05-23 CN CN201880035246.9A patent/CN111183148A/zh not_active Withdrawn
- 2018-05-23 AU AU2018272911A patent/AU2018272911B2/en not_active Ceased
- 2018-05-23 WO PCT/EP2018/063476 patent/WO2018215525A1/fr not_active Ceased
- 2018-05-23 RU RU2019141031A patent/RU2019141031A/ru unknown
- 2018-05-23 EP EP18730247.6A patent/EP3630805A1/fr not_active Withdrawn
- 2018-05-23 MA MA048956A patent/MA48956A/fr unknown
- 2018-05-23 US US16/614,454 patent/US20200079829A1/en not_active Abandoned
- 2018-05-23 BR BR112019024102-7A patent/BR112019024102A2/pt not_active Application Discontinuation
- 2018-05-23 PE PE2019002429A patent/PE20200514A1/es unknown
- 2018-05-23 US US15/986,961 patent/US10398782B2/en active Active
2019
- 2019-11-15 PH PH12019550241A patent/PH12019550241A1/en unknown
- 2019-11-25 CL CL2019003441A patent/CL2019003441A1/es unknown
- 2019-12-06 CO CONC2019/0013768A patent/CO2019013768A2/es unknown
2022
- 2022-12-19 US US18/083,729 patent/US20230364248A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US10398782B2 (en)	2019-09-03
US20230364248A1 (en)	2023-11-16
MA48956A (fr)	2020-04-08
PH12019550241A1 (en)	2020-12-07
US20180339057A1 (en)	2018-11-29
TWI710377B (zh)	2020-11-21
JP7015322B2 (ja)	2022-02-02
TW201900219A (zh)	2019-01-01
RU2019141031A3 (fr)	2021-07-16
AU2018272911A1 (en)	2019-12-19
EP3630805A1 (fr)	2020-04-08
WO2018215525A1 (fr)	2018-11-29
CL2019003441A1 (es)	2020-05-08
CA3064320A1 (fr)	2018-11-29
WO2018215525A8 (fr)	2020-01-02
CO2019013768A2 (es)	2020-04-01
US20200079829A1 (en)	2020-03-12
JP2020520918A (ja)	2020-07-16
KR20200010353A (ko)	2020-01-30
AU2018272911B2 (en)	2022-09-08
PE20200514A1 (es)	2020-03-05
BR112019024102A2 (pt)	2020-06-02
CN111183148A (zh)	2020-05-19
RU2019141031A (ru)	2021-06-16

Publication	Publication Date	Title
PH12019550241A1 (en)	2020-12-07	Mic-1 compounds and uses thereof
PH12018502465A1 (en)	2019-04-08	Mic-1 compounds and use thereof
TW201613958A (en)	2016-04-16	MIC-1 fusion proteins and uses thereof
EP4299118A3 (fr)	2024-04-10	Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
MY187047A (en)	2021-08-27	Selective pyy compounds and uses thereof
PH12020550051A1 (en)	2020-10-19	Glp-1 compositions and uses thereof
PH12021550705A1 (en)	2021-11-03	Stable semaglutide compositions and uses thereof
WO2015191781A3 (fr)	2016-07-21	Polypeptides d'apéline
MY161773A (en)	2017-05-15	Amylin analogues and pharmaceutical compositions thereof
WO2020123795A3 (fr)	2020-08-27	Anellosomes pour administrer des modalités thérapeutiques de remplacement de protéines
WO2017093810A3 (fr)	2017-08-24	Composition destinée à une administration intra-orale de peptides et de protéines biologiquement actifs
PH12021552741A1 (en)	2022-07-11	Solid forms of a glyt1 inhibitor
EP4653537A3 (fr)	2026-01-07	Rhodopsin-gentherapie zur regeneration des sehvermögens oder zur verhinderung der abnahme des sehvermögens
MY205028A (en)	2024-09-28	Protein for treatment of inflammatory diseases
CR20220206A (es)	2022-06-16	Agonistas del receptor npy2
PH12021550122A1 (en)	2021-09-27	Solubilized apyrases, methods and use
EA201590601A1 (ru)	2015-08-31	Применение pedf-производных полипептидов для лечения остеоартрита
MX362058B (es)	2019-01-07	Péptido pntx(19) sintético, composición farmacéutica y uso.
MX2025015454A (es)	2026-02-03	Formulaciones/composiciones que comprenden ibrutinib
MX2019001153A (es)	2019-06-10	Peptidos ciclicos como antagonistas del receptor c5a.
WO2018200814A3 (fr)	2018-12-06	Peptides cycliques modifiés et leur utilisation thérapeutique
WO2015150468A3 (fr)	2016-07-14	Nouveaux analogues de protéine ifn bêta
PH12017501918A1 (en)	2018-03-19	Multi-peptide composition
MX2020009877A (es)	2021-01-08	Péptidos neutralizantes de miotoxina.
TR201721065A2 (tr)	2019-07-22	Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar